^
    Back
    Association details:
    Biomarker:EWSR1-NR4A3 fusion
    Cancer:Soft Tissue Sarcoma
    Drug:Sutent (sunitinib) (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Eur J Cancer
    Title:

    Activity of sunitinib in extraskeletal myxoid chondrosarcoma

    Excerpt:
    From July 2011, 10 patients with progressive metastatic translocated EMC have been consecutively treated with sunitinib...Interestingly, all responsive cases turned out to express the typical EWSR1-NR4A3 fusion…
    DOI:
    10.1016/j.ejca.2014.03.013